Silicate ions as soluble form of bioactive ceramics alleviate aortic aneurysm and dissection

Aortic aneurysm and dissection (AAD) are leading causes of death in the elderly. Recent studies have demon-strated that silicate ions can manipulate multiple cells, especially vascular-related cells. We demonstrated in this study that silicate ions as soluble form of bioactive ceramics effectively alleviated aortic aneurysm and dissection in both Ang II and beta-BAPN induced AAD models. Different from the single targeting therapeutic drug approaches, the bioactive ceramic derived approach attributes to the effect of bioactive silicate ions on the inhibition of the AAD progression through regulating the local vascular microenvironment of aorta systematically in a multi-functional way. The in vitro experiments revealed that silicate ions did not only alleviate senescence and inflammation of the mouse aortic endothelial cells, enhance M2 polarization of mouse bone marrow-derived macrophages, and reduce apoptosis of mouse aortic smooth muscle cells, but also regulate their interactions. The in vivo studies further confirm that silicate ions could effectively alleviate senescence, inflammation, and cell apoptosis of aortas, accomplished with reduced aortic dilation, collagen deposition, and elastin laminae degradation. This bioactive ceramic derived therapy provides a potential new treatment strategy in attenuating AAD progression.

Automated summary

Silicate ions, as soluble form of bioactive ceramics, effectively alleviate aortic aneurysm and dissection by regulating the local vascular microenvironment and reducing senescence, inflammation, and cell apoptosis. In vitro experiments show that silicate ions can alleviate senescence, inflammation, and apoptosis of vascular-related cells and regulate their interactions. In vivo studies confirm that silicate ions can effectively alleviate aortic senescence, inflammation, and cell apoptosis, leading to reduced aortic dilation and elastin degradation. This bioactive ceramic derived therapy has the potential to attenuate AAD progression.